OBJECTIVE	To determine the impact of adjunctive Buchang Naoxintong Capsule ( , NXT ) on dual antiplatelet therapy in patients with cytochrome P450 2C19 * 2 ( CYP2C19 * 2 ) polymorphism undergoing percutaneous coronary intervention ( PCI ) .\